David Fuchs

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Gram-Negative Bacteria Aggravate Murine Small Intestinal Th1-Type Immunopathology following Oral Infection with <i>Toxoplasma gondii</i>

Markus M. Heimesaat, Stefan Bereswill, André Fischer et al. · The Journal of Immunology · 2006 · 346 citations · Full text

Veterinary Medicine, Immunology, Microbiology +17

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Christian F. Singer, Yen Y. Tan, Florian Fitzal et al. · Clinical Cancer Research · 2017 · 58 citations

Medicine, Molecular Biology, Oncology +16

Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial

Theresa Westphal, Gabriel Rinnerthaler, Simon Peter Gampenrieder et al. · Cancer Medicine · 2018 · 35 citations · Full text

Medicine, Oncology, Rehabilitation Medicine +17

Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin

David Fuchs, Alex Kilbertus, K Kofler et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 31 citations · Full text

Life Sciences, Immunology, Pathology +9